The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016.
Burden
Children
Respiratory illness
Respiratory syncytial virus
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
11 04 2023
11 04 2023
Historique:
received:
23
09
2022
accepted:
27
03
2023
medline:
12
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses. We combined case-based surveillance and ecological data to generate a national estimate of the burden of RSV-associated acute respiratory illness (ARI) and severe acute respiratory illness (SARI) in South African children aged < 5 years (2011-2016), including adjustment for attributable fraction. We estimated the RSV burden by month of life in the < 1-year age group, by 3-month intervals until 2 years, and then 12 monthly intervals to < 5 years for medically and non-medically attended illness. We estimated a mean annual total (medically and non-medically attended) of 264,112 (95% confidence interval (CI) 134,357-437,187) cases of RSV-associated ARI and 96,220 (95% CI 66,470-132,844) cases of RSV-associated SARI (4.7% and 1.7% of the population aged < 5 years, respectively). RSV-associated ARI incidence was highest in 2-month-old infants (18,361/100,000 population, 95% CI 9336-28,466). The highest incidence of RSV-associated SARI was in the < 1-month age group 14,674/100,000 (95% CI 11,175-19,645). RSV-associated deaths were highest in the first and second month of life (110.8 (95% CI 74.8-144.5) and 111.3 (86.0-135.8), respectively). Due to the high burden of RSV-associated illness, specifically SARI cases in young infants, maternal vaccination and monoclonal antibody products delivered at birth could prevent significant RSV-associated disease burden.
Sections du résumé
BACKGROUND
Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses.
METHODS
We combined case-based surveillance and ecological data to generate a national estimate of the burden of RSV-associated acute respiratory illness (ARI) and severe acute respiratory illness (SARI) in South African children aged < 5 years (2011-2016), including adjustment for attributable fraction. We estimated the RSV burden by month of life in the < 1-year age group, by 3-month intervals until 2 years, and then 12 monthly intervals to < 5 years for medically and non-medically attended illness.
RESULTS
We estimated a mean annual total (medically and non-medically attended) of 264,112 (95% confidence interval (CI) 134,357-437,187) cases of RSV-associated ARI and 96,220 (95% CI 66,470-132,844) cases of RSV-associated SARI (4.7% and 1.7% of the population aged < 5 years, respectively). RSV-associated ARI incidence was highest in 2-month-old infants (18,361/100,000 population, 95% CI 9336-28,466). The highest incidence of RSV-associated SARI was in the < 1-month age group 14,674/100,000 (95% CI 11,175-19,645). RSV-associated deaths were highest in the first and second month of life (110.8 (95% CI 74.8-144.5) and 111.3 (86.0-135.8), respectively).
CONCLUSIONS
Due to the high burden of RSV-associated illness, specifically SARI cases in young infants, maternal vaccination and monoclonal antibody products delivered at birth could prevent significant RSV-associated disease burden.
Identifiants
pubmed: 37038125
doi: 10.1186/s12916-023-02853-3
pii: 10.1186/s12916-023-02853-3
pmc: PMC10088270
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Informations de copyright
© 2023. The Author(s).
Références
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S203-S209
pubmed: 34472574
Lancet. 2022 May 28;399(10340):2047-2064
pubmed: 35598608
Influenza Other Respir Viruses. 2020 Nov;14(6):622-629
pubmed: 31444997
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S180-S186
pubmed: 34472569
Influenza Other Respir Viruses. 2019 Sep;13(5):484-495
pubmed: 31187609
Clin Infect Dis. 2019 Aug 30;69(6):1036-1048
pubmed: 30508065
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Vaccine. 2020 Jun 2;38(27):4288-4297
pubmed: 32389494
PLoS One. 2013;8(2):e56882
pubmed: 23573177
Clin Infect Dis. 2018 Jan 6;66(1):95-103
pubmed: 29040527
Emerg Infect Dis. 2017 Jul;23(7):1124-1132
pubmed: 28628462
J Infect Dis. 2013 Dec 15;208 Suppl 3:S246-54
pubmed: 24265484
Vaccine. 2019 Nov 28;37(50):7394-7395
pubmed: 29395536
Lancet Glob Health. 2021 Aug;9(8):e1077-e1087
pubmed: 34166626
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S193-S202
pubmed: 34472578
PLoS One. 2015 Jul 08;10(7):e0132078
pubmed: 26154306
PLoS One. 2014 Aug 18;9(8):e105543
pubmed: 25133576
Pan Afr Med J. 2018 Aug 10;30:271
pubmed: 30637056
Influenza Other Respir Viruses. 2018 May;12(3):360-373
pubmed: 29210203
Wellcome Open Res. 2018 Jul 25;3:89
pubmed: 30175247
Open Microbiol J. 2011;5:144-54
pubmed: 22262987
PLoS One. 2015 Mar 18;10(3):e0118884
pubmed: 25786103
S Afr Med J. 2019 Apr 29;109(5):333-339
pubmed: 31131801
Clin Infect Dis. 2019 Feb 15;68(5):773-780
pubmed: 29961814
Lancet Glob Health. 2020 Oct;8(10):e1316-e1325
pubmed: 32971054